关于 COVID 疫苗对神经系统影响的系统回顾。

IF 1.1 Q4 PHARMACOLOGY & PHARMACY
Viswarupachari Tanguturi Yella, Sumit Pareek, Bhumika Meena, K S B S Krishna Sasanka, Pugazhenthan Thangaraju, Sree Sudha T Y
{"title":"关于 COVID 疫苗对神经系统影响的系统回顾。","authors":"Viswarupachari Tanguturi Yella, Sumit Pareek, Bhumika Meena, K S B S Krishna Sasanka, Pugazhenthan Thangaraju, Sree Sudha T Y","doi":"10.2174/0115748863273931231121072231","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims & objectives: </strong>The objective of this study was to conduct a systematic review of research pertaining to the COVID-19 vaccine and its association with neurological complications.</p><p><strong>Method: </strong>We performed a comprehensive search of the literature using Google Scholar, PubMed, and NCBI databases from December 2021 to December 2022. For Google Scholar, PubMed, and NCBI databases we used the following key search terms: \"neurological adverse effects\", \"COVID-19 vaccination\", \"SARS-CoV-2\", CNS complications, and CNS adverse effects. Two reviewer authors individually searched and assessed the titles and abstracts of all articles. The third reviewer resolved the disagreement between them. Data were documented regarding title, study location, type of study, type of COVID-19 vaccine, type of neurological complications/adverse effects, and sample size.</p><p><strong>Results: </strong>From our findings, it is confirmed that these neurological complications like GuillainBarre syndrome (23.6%), Neuromyelitis Optica spectrum disorder (5.5%), Neuropathy (6.9%), Transverse Myelitis (8.3%) and Acute disseminated Encephalomyelitis (4.1%) are majorly affected in most of the people. The increase in risks associated with SARS-CoV-2 infection far outweighs any previously reported associations with vaccination.</p><p><strong>Conclusion: </strong>We found no safety signal was observed between COVID-19 vaccines and the immune-mediated neurological events. Before assuming a causal relationship, the side effects of the COVID-19 vaccine should first be carefully examined to rule out known associated factors. Symptom onset was within two weeks of vaccination in the majority of cases; as such, this seems to be a high-risk period warranting vigilance.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Systematic Review of the COVID Vaccine's Impact on the Nervous System.\",\"authors\":\"Viswarupachari Tanguturi Yella, Sumit Pareek, Bhumika Meena, K S B S Krishna Sasanka, Pugazhenthan Thangaraju, Sree Sudha T Y\",\"doi\":\"10.2174/0115748863273931231121072231\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims & objectives: </strong>The objective of this study was to conduct a systematic review of research pertaining to the COVID-19 vaccine and its association with neurological complications.</p><p><strong>Method: </strong>We performed a comprehensive search of the literature using Google Scholar, PubMed, and NCBI databases from December 2021 to December 2022. For Google Scholar, PubMed, and NCBI databases we used the following key search terms: \\\"neurological adverse effects\\\", \\\"COVID-19 vaccination\\\", \\\"SARS-CoV-2\\\", CNS complications, and CNS adverse effects. Two reviewer authors individually searched and assessed the titles and abstracts of all articles. The third reviewer resolved the disagreement between them. Data were documented regarding title, study location, type of study, type of COVID-19 vaccine, type of neurological complications/adverse effects, and sample size.</p><p><strong>Results: </strong>From our findings, it is confirmed that these neurological complications like GuillainBarre syndrome (23.6%), Neuromyelitis Optica spectrum disorder (5.5%), Neuropathy (6.9%), Transverse Myelitis (8.3%) and Acute disseminated Encephalomyelitis (4.1%) are majorly affected in most of the people. The increase in risks associated with SARS-CoV-2 infection far outweighs any previously reported associations with vaccination.</p><p><strong>Conclusion: </strong>We found no safety signal was observed between COVID-19 vaccines and the immune-mediated neurological events. Before assuming a causal relationship, the side effects of the COVID-19 vaccine should first be carefully examined to rule out known associated factors. Symptom onset was within two weeks of vaccination in the majority of cases; as such, this seems to be a high-risk period warranting vigilance.</p>\",\"PeriodicalId\":10777,\"journal\":{\"name\":\"Current drug safety\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2024-01-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current drug safety\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0115748863273931231121072231\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748863273931231121072231","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

目的与目标:本研究旨在对有关 COVID-19 疫苗及其与神经系统并发症相关性的研究进行系统性综述:我们使用谷歌学术、PubMed 和 NCBI 数据库对 2021 年 12 月至 2022 年 12 月期间的文献进行了全面检索。在 Google Scholar、PubMed 和 NCBI 数据库中,我们使用了以下关键检索词:"神经系统不良反应"、"COVID-19 疫苗接种"、"SARS-CoV-2"、中枢神经系统并发症和中枢神经系统不良反应。两位审稿作者分别对所有文章的标题和摘要进行了检索和评估。第三位审稿人解决了他们之间的分歧。数据记录包括标题、研究地点、研究类型、COVID-19 疫苗类型、神经系统并发症/不良反应类型以及样本量:我们的研究结果证实,神经系统并发症如格林巴利综合症(23.6%)、神经脊髓炎谱系障碍(5.5%)、神经病变(6.9%)、横贯性脊髓炎(8.3%)和急性播散性脑脊髓炎(4.1%)是大多数人的主要并发症。与 SARS-CoV-2 感染相关的风险增加远远超过了之前报道的与疫苗接种相关的风险:我们发现 COVID-19 疫苗与免疫介导的神经系统事件之间没有安全信号。结论:我们发现 COVID-19 疫苗与免疫介导的神经事件之间没有安全信号。在假定两者之间存在因果关系之前,应首先仔细检查 COVID-19 疫苗的副作用,以排除已知的相关因素。大多数病例的症状在接种后两周内出现;因此,这似乎是一个需要警惕的高风险期。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A Systematic Review of the COVID Vaccine's Impact on the Nervous System.

Aims & objectives: The objective of this study was to conduct a systematic review of research pertaining to the COVID-19 vaccine and its association with neurological complications.

Method: We performed a comprehensive search of the literature using Google Scholar, PubMed, and NCBI databases from December 2021 to December 2022. For Google Scholar, PubMed, and NCBI databases we used the following key search terms: "neurological adverse effects", "COVID-19 vaccination", "SARS-CoV-2", CNS complications, and CNS adverse effects. Two reviewer authors individually searched and assessed the titles and abstracts of all articles. The third reviewer resolved the disagreement between them. Data were documented regarding title, study location, type of study, type of COVID-19 vaccine, type of neurological complications/adverse effects, and sample size.

Results: From our findings, it is confirmed that these neurological complications like GuillainBarre syndrome (23.6%), Neuromyelitis Optica spectrum disorder (5.5%), Neuropathy (6.9%), Transverse Myelitis (8.3%) and Acute disseminated Encephalomyelitis (4.1%) are majorly affected in most of the people. The increase in risks associated with SARS-CoV-2 infection far outweighs any previously reported associations with vaccination.

Conclusion: We found no safety signal was observed between COVID-19 vaccines and the immune-mediated neurological events. Before assuming a causal relationship, the side effects of the COVID-19 vaccine should first be carefully examined to rule out known associated factors. Symptom onset was within two weeks of vaccination in the majority of cases; as such, this seems to be a high-risk period warranting vigilance.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current drug safety
Current drug safety PHARMACOLOGY & PHARMACY-
CiteScore
2.10
自引率
0.00%
发文量
112
期刊介绍: Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信